Last reviewed · How we verify
Tetanus/diphtheria toxoids
Tetanus/diphtheria toxoids are inactivated bacterial toxins that stimulate the immune system to produce antibodies against tetanus and diphtheria toxins, providing protective immunity.
Tetanus/diphtheria toxoids are inactivated bacterial toxins that stimulate the immune system to produce antibodies against tetanus and diphtheria toxins, providing protective immunity. Used for Prevention of tetanus, Prevention of diphtheria.
At a glance
| Generic name | Tetanus/diphtheria toxoids |
|---|---|
| Sponsor | London School of Hygiene and Tropical Medicine |
| Drug class | Toxoid vaccine |
| Target | Tetanus toxin (tetanospasmin) and diphtheria toxin |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains chemically inactivated toxins produced by Clostridium tetani and Corynebacterium diphtheriae. These toxoids are unable to cause disease but retain immunogenicity, triggering B and T cell responses that generate protective antibodies (antitoxins) against the respective bacterial toxins. Upon exposure to the actual pathogens, these pre-formed antibodies neutralize the toxins and prevent disease.
Approved indications
- Prevention of tetanus
- Prevention of diphtheria
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Myalgia
- Headache
- Fatigue
Key clinical trials
- Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PHASE4)
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients (PHASE1)
- Long-Term PF-06651600 for the Treatment of Alopecia Areata (PHASE3)
- Immunosuppression and COVID-19 Boosters (PHASE3)
- Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine (PHASE1, PHASE2)
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies (PHASE3)
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tetanus/diphtheria toxoids CI brief — competitive landscape report
- Tetanus/diphtheria toxoids updates RSS · CI watch RSS
- London School of Hygiene and Tropical Medicine portfolio CI